Stephen DiPalma

Stephen J.
DiPalma is the founder of Blueprint Genetics, Inc. (founded in 1988) and Catalyst Oncology, Inc. (founded in 2004).
He held the title of Chief Financial Officer at Blueprint Genetics, Inc. from 1988 to 1995 and the title of President & Chief Executive Officer at Catalyst Oncology, Inc. Mr. DiPalma's current job(s) included being a Director at Phytera, Inc. since 1998 and a Co-Managing Director at Danforth Advisors LLC since 2014.
Mr. DiPalma's former job(s) include being a Director at Cognoptix, Inc., Chief Financial Officer at Aquila Biopharmaceuticals, Inc., Chief Financial Officer at Interleukin Genetics, Inc. from 2014 to 2017, Chief Financial Officer & Senior Vice President at FORUM Pharmaceuticals, Inc. from 2009 to 2014, Chief Financial Officer at Histogenics Corp.
in 2015, Chief Financial Officer & EVP-Business Operations at Galena Biopharma, Inc. in 2009, Chief Financial Officer at Scorpius Holdings, Inc., Chief Financial Officer at Anchiano Therapeutics Ltd. in 2020, Chief Financial Officer at Milkhaus Laboratory, Inc. from 2002 to 2004, Divisional Controller at The Health Data Institute, Inc., Chief Financial Officer & Treasurer at Spero Therapeutics, Inc. from 2019 to 2021, Chief Financial Officer & Treasurer at Spero Therapeutics, Inc. in 2023, Chief Financial & Accounting Officer at Beyond Air, Inc. in 2018, Treasurer, Chief Financial & Accounting Officer at Solid Biosciences, Inc. from 2021 to 2023, Chief Financial & Accounting Officer at Inozyme Pharma, Inc., Chief Financial & Accounting Officer at Generation Bio Co. from 2019 to 2020, Chief Financial Officer at LAVA Therapeutics NV, Chief Financial Officer at CG Oncology, Inc., and Chief Financial Officer & Treasurer at Foghorn Therapeutics, Inc. in 2024.
Mr. DiPalma's education history includes an MBA from Babson College in 1988 and an undergraduate degree from the University of Massachusetts Lowell.